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PURPOSE. To determine if IL-17 regulates Mer tyrosine kinase–positive (MerTKþ) cells in
Pseudomonas aeruginosa keratitis.
METHODS. Interleukin 17 was tested in normal and infected cornea of susceptible C57BL/6 and
resistant BALB/c mice. The latter were treated with recombinant mouse (rm) IL-17; both
groups were treated with IL-17 neutralizing antibody. Mice were infected, and clinical score,
PCR, ELISA, and myeloperoxidase (MPO) assays tested expression of proinflammatory and
anti-inflammatory mediators and polymorphonuclear neutrophilic leukocyte (PMN) infiltrate.
Fas and Fas ligand (FasL) protein levels were assessed in both mouse strains, while MerTKþ
cells were examined by immunostaining and cell sorting before and after IL-17 neutralization.
RESULTS. The IL-17 mRNA and protein were higher in C57BL/6 versus BALB/c cornea after
infection. The rmIL-17 treatment of BALB/c mice modified proinflammatory and anti-
inflammatory mediators, but clinical score and MPO assay revealed no differences. However,
only BALB/c mice treated with IL-17 neutralizing antibody showed increased disease,
macrophage inflammatory protein (MIP) 2, and MPO levels. Fas and FasL protein levels,
elevated earlier in BALB/c versus C57BL/6 mice, correlated with significantly more MerTKþ
cells in BALB/c cornea at 3 days after infection. Neutralization of IL-17 in C57BL/6 mice
elevated MerTKþ cells, while similar treatment of BALB/c mice significantly decreased them.
CONCLUSIONS. These data provide evidence that IL-17 expression is higher in C57BL/6 versus
BALB/c cornea after infection and that the latter group has more MerTKþ cells. Exogenous
rmIL-17 failed to shift the disease response in resistant mice, but its neutralization resulted in
worsened disease and reduced MerTKþ cells. Neutralization of IL-17 in C57BL/6 mice
increased MerTKþ cells but did not dramatically shift the disease response.
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Pseudomonas aeruginosa, an opportunistic, gram-negativebacteria, is one of the most common pathogens associated
with microbial keratitis1 and whose occurrence is closely
related to contact lens usage.2 Pseudomonas aeruginosa
keratitis progresses rapidly and elicits an acute inflammatory
response in cornea that contributes to eradication of the
bacterium. Unless precisely regulated, this inflammatory
response also leads to significant corneal damage such as
stromal destruction and loss of vision. Interventions are needed
to promote bacterial clearance, while limiting tissue damage
due to a rapid and extensive influx of inflammatory cells, the
majority of which are polymorphonuclear neutrophilic leuko-
cytes (PMNs).
Experimental murine models of the disease have been
established. T helper type 1 (Th1) responder mouse strains
such as C57BL/6 are susceptible (cornea perforates), whereas
Th2 responder strains such as BALB/c are resistant (cornea
heals).3 Host innate responses to bacterial infection are
primarily mediated by PMNs and macrophages. Studies4,5 have
provided evidence that a key regulatory molecule associated
with PMN infiltration and inflammation-associated tissue
damage in infectious diseases is IL-17.
Interleukin 17 has been mainly regarded as a proinflamma-
tory cytokine that contributes to the local inflammatory
response through increased production of various chemokines
and cytokines, including TNF-a, macrophage inflammatory
protein (MIP) 2, IL-1b, IL-6, and intercellular adhesion molecule
1 (ICAM-1), which are essential for migration and activation of
PMNs and tissue damage at the site of inflammation.6–8
Interleukin 17 is now emerging as critical for host defense
against bacteria, virus, and fungi. Previous investigations have
shown that topical IL-17 neutralization reduces corneal
pathology, PMN influx, and intracellular bacterial levels and
improves early outcome for P. aeruginosa keratitis in C57BL/6
mice.9 Neutralization of IL-17 also reduces the corneal lesion
severity in recurrent herpetic keratitis in BALB/c mice.10
Furthermore, Candida keratitis development was blocked after
neutralization of IL-17 activity in BALB/c mice.11 Interestingly,
there is now an accumulation of evidence for IL-17 being able
to exert anti-inflammatory action as well, depending upon the
tissue environment, nature of the host, and kinetics of the
response. Evidence shows that IL-17 is a negative regulator of
established allergic asthma.12 Neutralization of IL-17 augments
the allergic response, while exogenous IL-17 reduces pulmo-
nary eosinophil recruitment and bronchial hyperreactivity.
Others also have reported that neutralization of IL-17 markedly
enhances the severity of colitis in BALB/c mice13 and increases
periapical inflammatory bone destruction.14
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Earlier apoptosis of infiltrating PMNs and efficient clearance
of apoptotic cells lead to a rapid resolution of inflammation
and protect against tissue damage.15–17 Efficient clearance of
apoptotic cells requires M2c polarization and Mer tyrosine
kinase (MerTK) induction.17 Mer tyrosine kinase is a major
macrophage apoptotic cell receptor and enables M2c macro-
phages to clear apoptotic cells more efficiently. One study18
has shown that IL-17 critically stimulates proinflammatory M1
macrophage programming during removal of Yersinia pestis
infection in C57BL/6 mice, while another study19 reported that
IL-17 can stimulate differentiation of anti-inflammatory
MerTKþ macrophages in response to IL-10. The relationship
between IL-17 and MerTKþ cells, including macrophages
during P. aeruginosa keratitis, remains untested to date.
Thus, the present study investigated expression and
function of IL-17 in innate immunity to P. aeruginosa keratitis
in mice. Our data provide evidence that IL-17 mRNA and
protein levels are disparately upregulated in C57BL/6 (more)
versus BALB/c (less) cornea after infection and that BALB/c
mice have increased MerTKþ cells in cornea. In addition,
BALB/c mice treated with recombinant mouse (rm) IL-17 or IL-
17 neutralizing antibody provided evidence that exogenous
rmIL-17 does not significantly shift the disease response, while
neutralization of IL-17 results in worsened disease. Further-
more, neutralization of IL-17 in BALB/c mice decreased
MerTKþ cells compared with controls, while similar treatment
in C57BL/6 mice increased them, albeit not significantly.
METHODS
Corneal Infection
Eight-week-old female BALB/c (resistant) and C57BL/6 (sus-
ceptible) mice were purchased from The Jackson Laboratory
(Bar Harbor, ME, USA). Mice were anesthetized with ether,
placed beneath a stereoscopic microscope at 340 magnifica-
tion, and the cornea of the left eye wounded (three 1-mm
incisions) using a sterile 255/8-gauge needle. A 5-lL aliquot
containing 1 3 106 CFU/lL P. aeruginosa, strain 19660
(American Type Culture Collection, Manassas, VA, USA)
prepared as described before,3 was topically applied to the
corneal surface. Eyes were examined at 1 day after infection
and/or at times described below to ensure mice were infected
and to monitor disease. Animals were treated humanely and in
compliance with the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research.
Corneal Response to Infection
Disease was graded using the following scale20: 0 (clear or
slight opacity, partially or fully covering the pupil), þ1 (slight
opacity, covering the anterior segment), þ2 (dense opacity,
partially or fully covering the pupil), þ3 (dense opacity,
covering the anterior segment), and þ4 (corneal perforation).
Clinical score was recorded for each mouse after infection (1,
3, and 5 days) for statistical comparison of disease severity, and
photography with a slitlamp was used to illustrate disease.
rmIL-17 Treatment
The left eyes of BALB/c mice (n¼ 5/group/time) were injected
subconjunctivally with 1 lg/5 lL rmIL-17 protein (R&D
Systems, Minneapolis, MN, USA) or 5 lL PBS at 1 day before
infection. At 1 and 3 days after infection, each mouse was
injected intraperitoneally with 1 lg rmIL-17 diluted in 100 lL
PBS. Control mice similarly received an equal volume of PBS.
IL-17 and IL-10 Neutralizing Antibody Treatment
Rat anti-mouse IL-17 neutralizing antibody (R&D Systems) (10
lg/5 lL) or control rat IgG (Jackson ImmunoResearch
Laboratories, West Grove, PA, USA) (10 lg/5 lL) was given
subconjunctivally into the left eyes of BALB/c and C57BL/6
mice (n¼ 5/group/time) the day before infection. On 1 and 3
days after infection, an additional 150 lg/100 lL was injected
intraperitoneally; controls were similarly injected with IgG. Rat
anti-mouse IL-10 neutralizing antibody (R&D Systems) (10 lg/5
lL) or control rat IgG (Jackson ImmunoResearch Laboratories)
(10 lg/5 lL) was given subconjunctivally into the left eyes of
BALB/c mice (n¼ 5/group/time) the day before infection. At 1
and 3 days after infection, an additional 150 lg/100 lL was
injected intraperitoneally; controls were similarly injected with
IgG.
Real-Time RT-PCR
After killing, normal (uninfected) and infected corneas were
removed at 1 and 5 days after infection in BALB/c and C57BL/6
mice (n ¼ 5/group/time) for detection of IL-17 mRNA levels.
Corneas were harvested at 5 days after infection after rmIL-17
treatment or PBS treatment and after IL-17 neutralizing
antibody treatment or IgG treatment. Total corneal RNA was
extracted (RNA STAT-60; Tel-Test, Friendswood, TX, USA)
according to the manufacturer’s instructions and was used to
produce a cDNA template for PCR reaction. After spectropho-
tometric quantification (260 nM), 1 lg of each RNA sample was
reverse transcribed using Moloney murine leukemia virus (M-
MLV) reverse transcriptase. The 20-lL reaction mixture
contained 10 U RNasin, 500 lg oligodeoxythymidylic acid
(oligo dt) primers, 10 mM deoxyribonucleotide triphosphates,
100 mM dithiothreitol, and M-MLV reaction buffer (all from
Invitrogen, Carlsbad, CA, USA). The cDNA products were
diluted 1:25 with diethylpyrocarbonate-treated water, and a 2-
lL cDNA aliquot was used for real-time RT-PCR (10-lL total
reaction volume). The mRNA levels of IL-17, MIP-2, IL-1b, TNF-
a, IL-6, IFN-c, ICAM-1, and IL-10 were tested by real-time RT-
PCR (CFX Connect Detection System; Bio-Rad, Hercules, CA,
USA). Real-time SYBR Green/Fluorescein PCR Master Mix (Bio-
Rad) was used for PCR reaction with primer concentrations of
5 lM. Optimal conditions for PCR amplification of cDNA were
established using routine methods.21 Relative transcription
levels were calculated using the relative standard curve
method that compares the amount of target normalized to
the endogenous reference gene b-actin. The primer pair
sequences used for real-time RT-PCR are listed in the Table.
ELISA Analysis
All individual corneas taken for ELISA analysis were homoge-
nized in 500 lL PBS with 0.1% Tween 20 (Sigma-Aldrich Corp.,
St. Louis, MO, USA) with a protease inhibitor cocktail (Roche
Diagnostics, Indianapolis, IN, USA) and centrifuged at 12,000g
for 5 minutes. Normal (uninfected) and infected corneas were
removed at 1, 3, and/or 5 days after infection from BALB/c and
C57BL/6 mice (n ¼ 5/group/time), and 50 lL of each sample
was assayed in duplicate for IL-17 and 100 lL for Fas and Fas
ligand (FasL) (normal and 1 and 3 days after infection)
according to the manufacturer’s instructions (R&D Systems).
After rmIL-17 or PBS treatment in BALB/c mice or after IL-17
neutralizing antibody or IgG treatment of both mouse strains,
normal and infected samples were harvested and prepared as
described above at 3 and 5 days after infection. An aliquot
(either 25 or 50 lL) of each supernatant was assayed in
duplicate for TNF-a, MIP-2, and IL-1b protein (R&D Systems).
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Quantitation of Corneal PMNs
A myeloperoxidase (MPO) assay was used to quantitate PMN
number. Corneas (n¼ 5/group/time) were removed at 3 and 5
days after infection and homogenized in 1.0 mL 50 mM
phosphate buffer (pH 6.0) containing 0.5% hexadecyltrimeth-
yl–ammonium bromide (Sigma-Aldrich Corp.). Samples were
freeze-thawed four times, and after centrifugation 100 lL
supernatant was added to 2.9 mL 50 mM phosphate buffer
containing o-dianisidine dihydrochloride (16.7 mg/100 mL)
and hydrogen peroxide (0.0005%). The change in absorbency
(460 nm) was monitored for 5 minutes at 30-second intervals.
The slope of the line was determined for each sample and was
used to calculate units of MPO per cornea. One unit of MPO
activity is equivalent to approximately 2 3 105 PMNs.22
Immunofluorescent Staining
Eyes were enucleated (n ¼ 3/group/time) at 3 days after
infection from BALB/c and C57BL/6 mice, immersed in 0.01 M
PBS, embedded in optimum cutting temperature compound
(Tissue-Tek; Miles, Elkhart, IN, USA), and frozen in liquid
nitrogen. Twelve-micrometer sections were cut, mounted to
poly-L-lysine–coated glass slides, and stored at 378C overnight.
After a 2-minute fixation in acetone, slides were blocked with
0.01 M PBS containing 2.5% BSA and goat IgG (1:100) for 30
minutes at room temperature. To identify IL-17–producing cell
types, sections were incubated for 1 hour with a 1:100 dilution
of either rat anti-mouse F4/80 antibody (Santa Cruz Biotech-
nology, San Jose, CA, USA) to label macrophages or rat anti-
mouse NIMP-R14 (Abcam, Cambridge, MA, USA) to label
PMNs. This was followed by the first secondary antibody,
AlexaFluor 546–conjugated goat anti-rat antibody (1:1500), for
either F4/80 or NIMP-R14 (Life Technologies, Carlsbad, CA,
USA) for another hour. Then, the second primary was
incubated sequentially at a 1:50 dilution of rat anti-mouse IL-
17 (Novus Biologicals, Littleton, CO, USA). This was followed
by the corresponding secondary antibody, AlexaFluor 647–
conjugated goat anti-rat antibody, at 1:1500 for 1 hour. Sections
were then incubated for 2 minutes with SYTOX Green Nuclear
Acid Stain (1:30,000; Lonza, Walkersville, MD, USA). Controls
were similarly treated, but the primary antibodies were
replaced with the same host IgG (Jackson ImmunoResearch
Laboratories). In another series of experiments, after a 2-
minute fixation in acetone, slides were blocked with 0.01 M
PBS containing 2.5% BSA and goat IgG (1:100) for 30 minutes
at room temperature. To label macrophages, the sections were
incubated at a 1:100 dilution of rat anti-mouse F4/80 (Santa
Cruz Biotechnology) for 1 hour. This was followed by the first
secondary antibody, AlexaFluor 546–conjugated goat anti-rat
antibody (Life Technologies), at 1:1500 for 1 hour. To label
MerTKþ cells, the second primary was incubated sequentially
for 1 hour with a 1:30 dilution of rat anti-mouse MerTK (R&D
Systems). This was followed by the corresponding secondary
antibody, AlexaFluor 647–conjugated goat anti-rat antibody, at
1:1500 for 1 hour. Sections were incubated for 2 minutes with
SYTOX Green Nuclear Acid Stain (Lonza) as described above.
Controls were similarly treated, but the primary antibodies
were replaced with the same host IgG as above. Finally,
sections were visualized and digital images captured with a
confocal laser scanning microscope (Leica TCS SP 8; Leica
Microsystems, Buffalo Grove, IL, USA).
Histopathology
For histopathological analysis, whole eyes were enucleated
from three mice from each experimental group (rmIL-17–
treated and PBS-treated BALB/c mice) at 3 days after infection.
Enucleated eyes were immersed in PBS, rinsed, and placed in a
fixative containing 1% osmium tetroxide, 2.5% glutaraldehyde,
and 0.2 M Sorenson’s phosphate buffer, pH 7.4 (1:1:1), at 48C
for a total of 3 hours. Eyes were transferred into fresh fixative
after 1.5 hours, dehydrated in graded ethanols, and embedded
in Epon-Araldite (Electron Microscopy Sciences, Hatfield, PA,
USA). Thick sections (1.5 lm) were cut, stained with a
modified Richardson’s stain, and observed. Representative
sections were photographed with a Leica DM4000b bright-
field microscope (Leica Microsystems).
Staining and Quantitation of F4/80þ and MerTKþ
Cells
Individual corneas from C57BL/6 and BALB/c mice, corneas
from both strains after IL-17 antibody or IgG control treatment,
and BALB/c corneas after IL-10 antibody or IgG treatment were
harvested at 3 days after infection and incubated in 1 mL (1
mg/mL) type I collagenase (Sigma-Aldrich Corp.) in Hanks’
TABLE. Nucleotide Sequences of Mouse Primers for Real-time RT-PCR
Gene Name GenBank Accession No. Primer Sequence (50–30) Size, Base Pair
b-Actin NM_007393.3 F-GAT TAC TGC TCT GGC TCC TAG C 147
R-GAC TCA TCG TAC TCC TGC TTG C
IL-17 NM_010552.3 F-TTT AAC TCC CTT GGC GCA AAA 165
R-CTT TCC CTC CGC ATT GAC AC
MIP-2 NM_009140.2 F-TGT CAA TGC CTG AAG ACC CTG CC 126
R-AAC TTT TTG ACC GCC CTT GAG AGT GG
IL-1b NM_008361.3 F-CGC AGC AGC ACA TCA ACA AGA GC 111
R-TGT CCT CAT CCT GGA AGG TCC ACG
TNF-a NM_013693.2 F-ACC CTC ACA CTC AGA TCA TCT T 148
R-GGT TGT CTT TGA GAT CCA TGC
IL-6 NM_031168.1 F-CAC AAG TCC GGA GAG GAG AC 141
R-CAG AAT TGC CAT TGC ACA AC
IFN-c NM_008337.3 F-GTT ACT GCC ACG GCA CAG TCA TTG 125
R-ACC ATC CTT TTG CCA GTT CCT CCA G
ICAM-1 NM_010493.2 F-GTC CGC TGT GCT TTG AGA ACT 74
R-CGG AAA CGA ATA CAC GGT GAT
IL-10 NM_010548.2 F-TGC TAA CCG ACT CCT TAA TGC AGG AC 126
R-CCT TGA TTT CTG GGC CAT GCT TCT C
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balanced salt solution (Invitrogen) containing 5% fetal bovine
serum (FBS) for 2 to 3 hours at 378C. The samples were
pipetted several times every 15 minutes to aid in dissociation
of the cornea. Cell suspensions were centrifuged at 300g at 48C
for 5 minutes to pellet cells. Cells in suspension were fixed for
10 minutes in methanol at208C. Cells were centrifuged, and
the cell pellet was washed with PBS containing 5% FBS. Cell
suspensions were incubated in 100 lL PBS with 5% FBS
containing goat anti-MerTK (R&D Systems) and rat anti-
macrophage (F4/80; Santa Cruz Biotechnology) diluted 1:10
and 1:20, respectively, for 1 hour on ice. After washing in 500
lL PBS with 5% FBS, the cell suspension was incubated in 100
lL PBS with 5% FBS containing FITC-conjugated donkey anti-
rat IgG (H þ L) and R-phycoerythrin–conjugated donkey anti-
goat IgG (Hþ L) (Jackson ImmunoResearch Laboratories), each
diluted 1:50 for 1 hour on ice. Cells were washed with 500 lL
PBS with 5% FBS, and positive cells were counted on a
Cellometer Vision (Nexcelom Biosciences, Lawrence, MA,
USA). Data are expressed as the number of positively stained
cells. Viability of cells for all experiments was greater than 85%.
Statistical Analysis
The difference in clinical score between two groups at each
time was tested by the Mann-Whitney U test. An unpaired, two-
tailed Student’s t-test was used to determine the statistical
significance of real-time RT-PCR, MPO, ELISA, and cell-sorting
data. Data were considered significant at P  0.05. All
experiments were repeated once to ensure reproducibility,
and data from a representative experiment are shown as the
mean 6 SEM.
RESULTS
IL-17 Expression in Cornea of BALB/c and C57BL/6
Mice
To investigate the role of IL-17 in the mechanism by which
corneas of BALB/c mice are able to more efficiently and
effectively heal after P. aeruginosa–induced corneal infection,
whereas C57BL/6 corneas typically perforate, we tested mRNA
and protein levels of IL-17 in normal uninfected and infected
BALB/c and C57BL/6 corneas by real-time RT-PCR and ELISA.
Results indicated that relative IL-17 mRNA levels were
significantly higher in C57BL/6 over BALB/c mouse corneas
at 5 days after infection (Fig. 1A; P < 0.05). Interleukin 17 was
not detected in normal cornea of either group and was not
different at 1 day after infection. To confirm these data, IL-17
protein was examined by ELISA (Fig. 1B). Interleukin 17
protein was elevated in C57BL/6 over BALB/c mouse corneas
at 1, 3, and 5 days after infection (P < 0.01, P < 0.05, and P <
0.05, respectively). No IL-17 protein was detected in the
normal cornea of either group. Dual immunostaining was used
for both groups of mice to detect whether macrophages and
PMNs expressed IL-17 in the infected cornea. Positive dual
staining (magenta) for F4/80þ macrophages (red) that
expressed IL-17 (blue) was seen in C57BL/6 (Fig. 1C) and
BALB/c (Fig. 1D) corneal stroma at 3 days after infection. The
F4/80þ macrophages that did not express IL-17 (Fig. 1D)
stained red. Controls (Fig. 1E) were negative for staining in
both groups but are only shown for BALB/c cornea. Dual
immunostaining (magenta) for PMNs (red) and IL-17 (blue) also
was observed at 3 days after infection for both C57BL/6 (Fig.
1F) and BALB/c (Fig. 1G) infected cornea, and controls were
negative (Fig. 1H) for both groups but are only shown for
C57BL/6 cornea.
rmIL-17 Treatment of BALB/c Mice
Given the divergent expression of IL-17 in resistant BALB/c
versus susceptible C57BL/6 mice, as demonstrated at the
mRNA (real-time RT-PCR) and protein (ELISA) levels in infected
corneas, resistant BALB/c mice were treated with rmIL-17 to
test whether increased levels of IL-17 resulted in worsened
disease. Treatment with rmIL-17 did not significantly alter
disease outcome at any time tested, as indicated by clinical
score (Fig. 2A) and slitlamp photography comparing PBS-
treated (Fig. 2B) and rmIL-17–treated (Fig. 2C) BALB/c mice at
5 days after infection. Next, we examined the effects of rmIL-
17 treatment regarding corneal production of proinflammatory
and anti-inflammatory cytokine expression after infection.
After treatment with rmIL-17, corneal IL-17 mRNA levels were
significantly decreased at 5 days after infection (Fig. 2D; P <
0.01) compared with control-treated mice. Treatment with
rmIL-17 compared with PBS also significantly decreased mRNA
levels of proinflammatory cytokine IL-6 (Fig. 2E; P < 0.05),
while IFN-c mRNA was elevated in the recombinant protein
over control group at 5 days after infection; the difference was
not significant (Fig. 2F). The ICAM-1 was decreased (Fig. 2G; P
< 0.01) at this time. The anti-inflammatory mediator IL-10 was
downregulated in rmIL-17–treated mice compared with PBS-
treated mice (Fig. 2H; P < 0.001) at 5 days after infection. No
differences between groups for normal cornea were detected
(Figs. 2D–H). Moreover, corneal mRNA and protein levels for
TNF-a, MIP-2, and IL-1b were tested. The PCR and ELISA data
showed lower TNF-a mRNA (Fig. 3A; P < 0.05) at 5 days after
infection and protein (Fig. 3B), but the latter was not
significantly decreased at any time tested. The MIP-2 mRNA
(Fig. 3C; P < 0.001) and MIP-2 protein (Fig. 3D; P < 0.05) at 5
days after infection were significantly reduced. The IL-1b
mRNA (Fig. 3E; P < 0.01) was decreased after rmIL-17
treatment, but protein levels did not differ between the two
groups (Fig. 3F). In addition, MPO levels, reflecting the PMN
infiltrate, did not differ significantly between the two groups
(Fig. 3G) at either 3 or 5 days after infection. The cell infiltrate
was also examined histopathologically at 3 days after infection,
and reflective of the MPO data, tissue sections showed a
similarity of infiltrating cell type, mainly PMNs, in both PBS-
treated (Fig. 4A) and rmIL-17–treated (Fig. 4B) BALB/c mouse
cornea.
IL-17 Neutralizing Antibody Treatment of BALB/c
and C57BL/6 Mice
Since treatment with rmIL-17 did not result in significantly
changed disease outcome, BALB/c mice were treated with IL-
17 neutralizing antibody. No significant difference in clinical
scores was seen early (1 and 3 days after infection), but by 5
days after infection clinical score was significantly higher in
antibody-treated compared with IgG-treated mice. Corneal
perforation (þ4) occurred in 40% of mice after IL-17
neutralizing antibody treatment versus lower scores (þ2) and
no perforation in IgG control mice (Fig. 5A; P < 0.05).
Photographs taken using a slitlamp at 5 days after infection
(Figs. 5B, 5C) illustrate the disease response in IgG control
mice (þ2) (Fig. 5B) versus IL-17 antibody–treated mice (þ3)
(Fig. 5C). Antibody treatment also significantly increased
mRNA levels of IL-17 (Fig. 5D; P < 0.01) at 5 days after
infection, while levels of IL-6 (Fig. 5E) were decreased but not
significantly. The IFN-c (Fig. 5F; P < 0.01) was increased after
neutralization, while ICAM-1 (Fig. 5G; P < 0.05) was slightly
decreased at 5 days after infection. The IL-10 (Fig. 5H; P <
0.05) mRNA levels were significantly upregulated in IL-17
antibody–treated compared with IgG-treated BALB/c mice at 5
days after infection. Moreover, PCR and ELISA data showed that
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TNF-a mRNA was decreased (Fig. 6A; P < 0.05), while protein
levels were enhanced (Fig. 6B; P < 0.01) at 5 days but not at 3
days after infection in antibody-neutralized over control-treated
mice. The MIP-2 (Fig. 6C; P < 0.05) and IL-1b (Fig. 6E; P <
0.05) mRNA levels decreased at 5 days after infection, while
MIP-2 protein (Fig. 6D) decreased at 3 days after infection (P <
0.05) but increased at 5 days after infection (P < 0.01) in
antibody versus IgG controls. The IL-1b protein levels did not
change significantly between the two groups (Fig. 6F) at 3 or 5
days after infection. The MPO levels, indicative of PMN
infiltrate (Fig. 6G), decreased at 3 days after infection (P <
0.05) but increased at 5 days after infection (P < 0.001) after
IL-17 neutralization.
The C57BL/6 mice were similarly treated with IL-17
neutralizing antibody (Figs. 7A–G). The mean clinical scores
between the two groups did not differ at any time tested (Fig.
7A), nor were there visible differences between IgG-treated
(Fig. 7B) and IL-17 antibody–treated (Fig. 7C) groups (visual-
ized by slitlamp photography). No differences in protein levels
were observed between groups for MIP-2 (Fig. 7D), IL-1b (Fig.
7E), or TNF-a (Fig. 7F). Consistent with these data, MPO levels
also did not differ between groups at either 3 or 5 days after
infection (Fig. 7G).
Fas and FasL Expression and the Number of
MerTKþ Cells in BALB/c Versus C57BL/6 Mice
Since we have shown before that the pattern of apoptosis
occurs earlier in BALB/c versus C57BL/6 mice15,16 and because
among MerTKþ cells macrophages expressing the receptor are
critical in apoptotic PMN removal and IL-10 secretion,17,19 we
tested protein levels of Fas and FasL in the normal cornea and
FIGURE 1. (A–H) Expression and sources of IL-17 in corneas of C57BL/6 and BALB/c mice. Relative mRNA levels of IL-17 (A) were significantly
greater in the infected cornea of C57BL/6 versus BALB/c mice at 5 days after infection. No difference was detected between C57BL/6 and BALB/c
mice at 1 day after infection. Protein levels of IL-17 (B) were significantly increased in the infected cornea of C57BL/6 versus BALB/c mice at 1, 3,
and 5 days after infection. Interleukin 17 was not detected in the normal cornea of either group (mRNA and protein). Dual immunostaining
(magenta) for IL-17 (blue) and macrophages (F4/80; red) in the C57BL/6 cornea (C) and BALB/c cornea (D) at 3 days after infection. Dual
immunostaining (magenta) for IL-17 (blue) and PMNs (NIMP-R14; red) in the C57BL/6 (F) and BALB/c (G) cornea at 3 days after infection. Nuclei
are labeled with SYTOX Green Nuclear Acid Stain (Lonza) (green). Primary antibody was replaced with species-specific IgG in control sections,
which were positive for SYTOX Green Nuclear Acid Stain (Lonza) only (E, H). Magnification: 3450 (C–H).
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after infection in both strains of mice. Results indicated that Fas
(Fig. 8A) protein levels were elevated earlier in BALB/c versus
C57BL/6 mice. At 1 day after infection, higher levels of Fas
protein were detected in BALB/c versus C57BL/6 mice (P ¼
0.02), while at 3 days after infection more Fas was detected in
C57BL/6 mice (P¼ 0.0001); a higher level of protein also was
seen in the normal BALB/c mouse cornea (P ¼ 0.0001). The
FasL protein levels were greater in the normal cornea of BALB/
c versus C57BL/6 mice and at 1 day after infection (Fig. 8B; P¼
0.0002 and P ¼ 0.008, respectively). At 3 days after infection,
C57BL/6 mice showed higher levels of the protein over BALB/c
mice (P ¼ 0.007). Immunostaining and cell sorting were used
to detect whether differences in MerTKþ cells correlated with
the apoptotic pattern described above. Dual-label immuno-
staining at 3 days after infection revealed that MerTKþ
macrophages are present in cornea of C57BL/6 (Fig. 8C) and
BALB/c (Fig. 8E) mice; the respective controls (Figs. 8D, 8F)
were both negative. In order to detect whether differences in
the number of F4/80 and MerTKþ cells existed between the
two groups, cell sorting was used, and at 3 days after infection
more F4/80þ macrophages were detected in BALB/c over
C57BL/6 mice (P ¼ 0.007). The MerTKþ cells (macrophages
among them) also were sorted, and at 3 days after infection
BALB/c mice had significantly more positive cells (P ¼ 0.003)
than C57BL/6 mice.
FIGURE 2. (A–H) The rmIL-17 treatment of BALB/c mice. Similar clinical scores (A) were seen at 1, 3, and 5 days after infection in rmIL-17–treated
compared with PBS-treated mice. Photographs taken with a slitlamp at 5 days after infection showed similar disease after PBS (B) compared with
rmIL-17 (C) treatment. After rmIL-17 treatment, relative mRNA levels of IL-17 (D), IL-6 (E), and ICAM-1 (G) were significantly decreased in the
infected cornea of BALB/c mice at 5 days after infection. There was no difference in mRNA expression of IFN-c (F) between treatment groups at 5
days after infection. The mRNA levels of IL-10 (H) were significantly decreased in rmIL-17 compared with PBS controls at 5 days after infection. The
IL-17, IL-6, IFN-c, and IL-10 mRNA was not detected in the normal cornea of either group; no differences between groups were seen for ICAM-1 in
the normal cornea. Magnification: 35 (B, C).
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FIGURE 3. (A–G) Effects of rmIL-17 treatment on TNF-a, MIP-2, IL-1b, and MPO levels. The TNF-a mRNA (significantly) and protein (not significant)
levels were decreased (A, B) at 5 days after infection in rmIL-17–treated over PBS control mice. In addition, MIP-2 mRNA (C) and protein (D) levels
were both significantly decreased at 5 days after infection. No differences in protein levels were detected at 3 days after infection. The IL-1b mRNA
(E) was significantly decreased after rmIL-17 treatment at 5 days after infection, while protein levels (F) did not differ between groups at either 3 or
5 days after infection. The MPO (G) levels did not differ between the two groups at either 3 or 5 days after infection. No differences were detected
for normal cornea between the two groups.
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Effect of IL-17 on MerTKþ Cells in BALB/c and
C57BL/6 Mice
Next, to investigate the effect of IL-17 on the number of
MerTKþ and F4/80þ cells, IL-17 neutralizing antibody was used
in C57BL/6 and BALB/c mice. Immunostaining and cell sorting
to determine the number of F4/80 and MerTKþ cells at 3 days
after infection showed that neutralization of IL-17 in C57BL/6
mice increased F4/80þ and MerTKþ cells (Fig. 9A) but not
significantly, while similar treatment of BALB/c mice decreased
both F4/80 (P ¼ 0.003) and MerTKþ (P ¼ 0.02) cells
significantly. However, as shown in Figures 9A and 9B, not all
MerTKþ cells are macrophages, nor are all macrophages
MerTKþ. To determine in BALB/c mice whether IL-10 was of
importance in the latter response, IL-10 was neutralized, and
data showed (Fig. 9C) that IL-10 neutralization compared with
IgG treatment did not affect either F4/80 or MerTKþ cell
number.
DISCUSSION
The IL-17 family members are emerging as key players in
immune responses.7 The first member to be identified, IL-17A
(also commonly called IL-17), is the prototype of the IL-17
family.23 Interleukin 17 is a proinflammatory cytokine that
contributes to the local inflammatory response through
increased production of various chemokines and cytokines
that are essential for migration and activation of PMNs and
tissue damage at the site of inflammation.24,25 It has been
reported that IL-17 is produced in cornea during P. aeruginosa
keratitis.9 Results presented in this study revealed that IL-17
was not detected in normal cornea and that after P. aeruginosa
infection its expression is disparately upregulated in C57BL/6
(more) versus BALB/c (less) corneas. These data, suggesting a
potential role for IL-17 in the development of susceptible
versus resistant phenotype, are consistent with results in a
previous study25 from another laboratory showing that P.
aeruginosa keratitis induced a strong Th17 cell response in
C57BL/6 mice that results in IL-17 production in cornea. Our
findings also are consistent with those in previous investiga-
tions in a murine model of Candida keratitis showing that IL-
17 was induced after infection and correlated with the
development of disease.11,26 In line with data from animal
investigations, IL-17 expression levels also were elevated in
corneas of herpetic stromal keratitis patients, while no IL-17
was detected in normal corneas.27
In our study, despite the disparate levels of IL-17 in cornea
between the two groups, we found that PMNs and macro-
phages in both strains of mice produced IL-17 in corneal
stroma after infection. While PMNs are thought to be the
predominant effector of Th17 cell responses, IL-17 is also
known to induce myelotropic chemokines and growth factors.
In fact, IL-17 signaling may elicit unique macrophage functions
based upon the anatomical compartment in which they reside.
The greatest expression of IL-17 receptors was observed on
mucosal macrophages, suggesting that macrophages from
different anatomical locations direct IL-17–mediated respons-
es.28 We did not examine other cell types, but classically
gamma delta T cells and another innate subtype of T cells that
expresses IL-17 during intestinal bacterial infection have
recently been identified.29 In fact, IL-17 can be produced by
several other innate immune cell types such as lymphoid
tissue–inducer cells, natural killer and natural killer T (NKT)
cells, macrophages, and Paneth cells.30,31 The functional
importance of the IL-17 produced by these cell types during
inflammation is not well characterized.
In this regard, IL-17 (and IL-17F) has protective roles in host
defense against several pathogens at epithelial and mucosal
barriers. A defect in IL-17 or IL-17RA results in increased
bacterial dissemination, correlating with reduced inflammatory
mediators and PMN recruitment.32 Human patients with hyper-
IgE syndrome, who have defective IL-17A/F production due to
a genetic mutation in the STAT3 gene, have high susceptibility
to Staphylococcus aureus, Streptococcus pneumoniae, and
Candida albicans infection, further supporting the protective
roles of IL-17 (and IL-17F) in immune responses against these
pathogens.33 Interleukin 17 (and IL-17F) mediates immunolog-
ical function by inducing proinflammatory cytokine, antipa-
thogenic peptide, and chemokine secretion by responder cells.
The release of these molecules signals recruitment of innate
immune cells to the site of infection and elimination of the
pathogen.
Previous investigators have reported that neutralization of
IL-17 during corneal P. aeruginosa infection reduced PMN
influx and pathology at 48 hours after infection in C57BL/6
mice.9 In order to fully determine the role of IL-17 in corneal P.
aeruginosa infection, rmIL-17 protein was given to resistant
BALB/c mice that had lower IL-17 expression than C57BL/6
mice to determine whether rmIL-17 increased the disease
response. Clinical score and slitlamp data showed that
injection of BALB/c mice with rmIL-17 protein did not
significantly alter disease outcome. Nonetheless, treatment
with rmIL-17 compared with PBS significantly decreased
mRNA levels of proinflammatory molecules such as IL-17,
MIP-2, IL-1b, TNF-a, IL-6, and the anti-inflammatory mediator
IL-10, while IFN-c mRNA levels did not differ between the two
groups. We also found lower MIP-2 protein levels after rmIL-17
FIGURE 4. (A, B) Light microscopic histopathology of P. aeruginosa–infected corneas from BALB/c mice treated with PBS (A) or rmIL-17 (B) at 3
days after infection. Insets in each panel show that PMNs are the predominant cell infiltrate for both groups. Magnification:335 (A, B) and 390 (A, B
insets).
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treatment at 5 days after infection, but protein levels for IL-1b,
TNF-a, and MPO (indicative of PMN infiltrate) did not differ
between the two groups. These findings are consistent with a
previous study34 showing that administration of rmIL-17 did
not significantly alter MPO activity and mRNA levels of IFN-c
on Helicobacter pylori–induced gastritis. Our in vivo data
suggest that exogenous IL-17 in a resistant mouse disrupts the
balance of proinflammatory and anti-inflammatory mediators
but is not sufficient to shift the disease response to
susceptibility or perforation. Our results provide evidence that
exogenous IL-17 may have multiple roles in the pathogenesis of
corneal P. aeruginosa infection in BALB/c mice, which is
consistent with the study by Ke et al.35 showing that IL-17 had
both proinflammatory and anti-inflammatory effects in exper-
imental autoimmune uveitis.
Since treatment with rmIL-17 did not significantly change
disease outcome, IL-17 neutralizing antibody was used to test if
decreasing IL-17 in BALB/c mice had an effect. Data provided
evidence that IL-17 neutralizing antibody did not significantly
change early disease (1 and 3 days after infection) clinical
scores, but at 5 days after infection clinical scores were
significantly higher in IL-17 antibody–treated compared with
IgG-treated mice. Our findings are consistent with studies
showing that neutralization of IL-17 markedly increased the
severity of colitis in BALB/c mice13 and that IL-17 neutralization
induced a significant increase in periapical inflammatory bone
destruction.14 In contrast, Zaidi et al.9 reported that neutral-
ization of IL-17 in C57BL/6 mice during corneal P. aeruginosa
infection reduced PMN influx and pathology at 48 hours after
infection. Thus, we also neutralized IL-17 in C57BL/6 mice, but
FIGURE 5. (A–H) Interleukin 17 neutralizing antibody treatment of BALB/c mice. Clinical scores (A) were similar at 1 and 3 days after infection but
were significantly higher in IL-17 antibody–treated compared with IgG-treated mice at 5 days after infection. Photographs taken by slitlamp at 5 days
after infection illustrate the disease response in IgG control mice (þ2) (B) versus IL-17 antibody–treated mice (þ3) (C). After IL-17 neutralization,
relative mRNA levels of IL-17 (D), IFN-c (F), and IL-10 (H) were significantly increased in the infected cornea of BALB/c mice at 5 days after
infection, while ICAM-1 (G) mRNA levels decreased. There was no difference in mRNA expression of IL-6 (E) between the two groups at 5 days after
infection. There were no differences between groups for normal cornea. Magnification: 35 (B, C).
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there was no change in clinical score, in levels of proteins
(including MIP-2, IL-1b, and TNF-a), or in MPO assay following
infection. The reason for these inconsistencies may be the use
of different bacterial strains, routes of delivery, and concentra-
tions of the neutralizing antibody, as well as the extended time
points used for our versus their experiments. Similar inconsis-
tency between neutralization of IL-17 and gene deletion of IL-
17 was also found. Flierl et al.36 reported that neutralization of
FIGURE 6. (A–G) Effects of IL-17 neutralizing antibody treatment on TNF-a, MIP-2, IL-1b, and MPO. After IL-17 neutralization, mRNA levels of TNF-a
(A), MIP-2 (C), and IL-1b (E) were significantly decreased in the infected cornea of BALB/c mice at 5 days after infection. The TNF-a protein (B) was
significantly increased at 5 days after infection after IL-17 neutralization. The MIP-2 protein (D) was significantly decreased in the infected cornea of
BALB/c mice at 3 days after infection but increased at 5 days after infection after IL-17 neutralization. The IL-1b protein (F) did not differ between
the two groups at either time tested. The MPO (G) levels were significantly decreased at 3 days after infection but increased at 5 days after infection
after IL-17 neutralization. Normal cornea (mRNA and protein) showed no difference between groups for normal cornea for TNF-a and no detectable
expression for either MIP-2 or IL-1b.
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IL-17 by antibody was protective by reducing bacteremia and
systemic levels of pro-inflammatory cytokines and chemokines
and by improving survival during polymicrobial sepsis in
C57BL/6 mice. In contrast, Ogiku et al.37 reported that the
survival rate of IL-17 knockout mice was significantly reduced
after sepsis and that a more severe degree of acute lung injury
was detected in the IL-17 knockout mice than in the wild-type
mice after sepsis. In addition, we found that IFN-c mRNA levels
were significantly upregulated in IL-17 antibody–treated
compared with IgG-treated BALB/c mice at 5 days after
infection. The MIP-2 protein and MPO decreased at 3 days
after infection but increased at 5 days after infection in IL-17
neutralizing antibody versus IgG controls. These findings are
consistent with a study34 showing that neutralization of IL-17
increased MPO activity and expression of mRNA for IFN-c on
H. pylori–induced gastritis. The IL-17RA knockout mice
expressed significantly higher levels of MIP-2 and elevated
accumulation of PMNs in infection-stimulated periapical bone
destruction.14 Our neutralization data showed that IL-17 is
needed for the resistance response of BALB/c mice and are
consistent with studies13,34 showing that IL-17 had anti-
inflammatory effects on H. pylori–induced colitis and gastritis.
Our previous studies15,16 have shown that PMN apoptosis
occurs earlier in BALB/c versus C57BL/6 mice. Early apoptosis
of PMNs leads to rapid resolution of inflammation. In addition,
we reported herein that Fas and FasL protein levels were
elevated earlier in BALB/c versus C57BL/6 mice, consistent
with earlier apoptosis in BALB/c mice. In this regard, work
FIGURE 7. (A–G) Interleukin 17 neutralizing antibody treatment of C57BL/6 mice. Similar clinical scores (A) were seen at 1, 3, and 5 days after
infection in IL-17 antibody–treated compared with IgG-treated mice. Photographs taken with a slitlamp at 5 days after infection showed similar
disease after IgG (B) compared with IL-17 antibody (C) treatment. After IL-17 neutralization, protein levels of MIP-2 (D), IL-1b (E), and TNF-a (F) did
not differ between the two groups at 3 or 5 days after infection. The MPO levels (G) also did not differ between groups for either time tested.
Magnification: 35 (B, C).
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from another laboratory38 has shown that, among the cells that
express MerTK, macrophages (a subset of M2 macrophages)
expressing this receptor are critical in apoptotic PMN removal
and IL-10 secretion.19 The MerTK receptor mediates phagocy-
tosis of apoptotic cells and modulates cytokine production; it is
also required for prevention of systemic autoimmune disease.
Using a Mer-specific antibody, Behrens et al.38 confirmed the
presence of Mer on macrophages but also detected its
expression on other innate immune cells, including NK,
NKT, and dendritic cells (DCs). They found that DCs do not
FIGURE 8. (A–G) Expression of Fas, FasL, and MerTKþmacrophages in corneas of C57BL/6 and BALB/c mice. Protein levels of Fas (A) were elevated
in normal cornea and earlier in BALB/c than C57BL/6 mice after infection. At 1 day after infection, more Fas was detected in BALB/c versus C57BL/6
mouse cornea, while at 3 days after infection C57BL/6 mice expressed more Fas protein. The FasL (B) was higher in normal BALB/c versus C57BL/6
mice and at 1 day after infection; C57BL/6 mice had higher levels at 3 days after infection. Dual immunostaining (magenta) for MerTK (blue) and
macrophages (F4/80; red) in the C57BL/6 (C) and BALB/c (E) cornea at 3 days after infection. Nuclei are labeled with SYTOX Green Nuclear Acid
Stain (Lonza) (green). Negative controls show only SYTOX Green Nuclear Acid Stain (Lonza) in the C57BL/6 (D) and BALB/c cornea (F).
Immunostaining and cell sorting showed that at 3 days after infection more MerTKþ cells and F4/80þ cells were counted in BALB/c versus C57BL/6
mice (G). Magnification: 3450 (C–F).
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require Mer for ingestion of apoptotic cells because DCs from
Mer-deficient mice phagocytose apoptotic cells normally. Mer
apparently participates in NKT cell antigen–induced signaling
because NKT cells from Mer-deficient mice demonstrated
much lower cytokine production after in vivo a-galactosylcer-
amide stimulation; this defect was intrinsic to the Mer-deficient
NKT cells. Taken together, these studies show Mer expression
on many cells of the innate immune system. Mer, through its
binding of lipid antigens, may not only mediate ingestion of
apoptotic cells but also signal events in NK cells, NKT cells,
and DCs. Little is known regarding MerTK cells and their role
in P. aeruginosa keratitis, but previous studies from this
laboratory have shown the importance of both NK cells39 and
NKT cells40 in bacterial keratitis. In BALB/c mice, NK cells
were shown to express the NK-1R and were required for
disease resolution through production of IFN-c. In C57BL/6
mice, NKT cells were critical to initiate an inflammatory
response, and their depletion (NKT or NK cells) resulted in
earlier corneal perforation. To date, nothing is known
regarding MerTK-expressing cells in the infected cornea.
Using dual immunostaining, we found both MerTKþ and
F4/80þ, as well as MerTK F4/80þ macrophages, in both the
C57BL/6 and BALB/c infected corneal stroma. These data are
consistent with other reports that not all human macrophage
subsets (e.g., M1 cells secreting IL-12 and promoting Th1
differentiation17) were positive for MerTK.
Using cell sorting, significantly more MerTKþ cells were
seen in BALB/c over C57BL/6 infected cornea at 3 days after
infection. Then, to determine the effect of IL-17 on this
population of MerTKþ cells further, antibody neutralization
and cell sorting were used. The IL-17 neutralization in C57BL/6
mice raised the level of both F4/80 and MerTKþ cells but did
not reach significance. In contrast, similarly treated BALB/c
mice showed a significant decrease in both F4/80 and MerTKþ
cell number and again confirmed that not all macrophages
were positive for MerTK. These data complement another
study41 showing that administration of IL-17 neutralizing
antibodies led to decreased M1 macrophages and increased
M2 (anti-inflammatory) macrophages (a decreased ratio of M1
to M2) in local necrotic lesions of the jawbone in C57BL/6
mice. These data suggest that lower levels of IL-17 in BALB/c
mice promote MerTKþ cells (including F4/80 macrophages) to
enhance the resistance response. Our findings are also
complementary to other investigations showing that IL-17 is
involved in stimulating macrophages from BALB/c mice to
phagocytize aged PMNs,42 but further work in the keratitis
model will be required to test that more specifically.
In addition, since investigators19 have reported that IL-17
can stimulate differentiation of anti-inflammatory MerTKþ cells
in response to IL-10, we neutralized IL-10 in BALB/c mice and
found no difference in the MerTK cell population at 3 days
after infection. These data were surprising because we have
shown that IL-10 recombinant protein together with rapamy-
cin treatment can rescue BALB/c mice from the deleterious
effects of inhibition of mammalian target of rapamycin by
administration of rapamycin, whereby IL-10 is reduced and IL-
12 is increased.43
In summary, the data presented herein indicate that IL-17 is
more highly expressed in C57BL/6 versus BALB/c mouse
cornea after infection. Exogenous rmIL-17 in a resistant (BALB/
c) mouse disrupts the balance of proinflammatory and anti-
inflammatory mediators but does not shift the disease response
to susceptibility or perforation. However, its neutralization
resulted in worsened disease in these mice. In addition, we
provide evidence that neutralization of IL-17 in C57BL/6 mice
increases MerTKþ cells, albeit not significantly, while similar
treatment of BALB/c mice decreases them, with significant
consequences and enhanced disease. Continued studies of IL-
17–expressing and MerTK-expressing cells appear critical and
may significantly enhance our understanding of protective
inflammation during pathogen infection. Further dissection of
the source and regulation of IL-17 expression and signaling
mechanisms may provide novel ways to modulate the immune
system in infectious and inflammatory diseases.
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FIGURE 9. (A–C) Effect of IL-17 neutralization on MerTKþ cells (and
macrophages) in BALB/c and C57BL/6 mice and IL-10 neutralization in
BALB/c mice. Increased MerTKþ cells and macrophages (F4/80þ) were
detected in IL-17 antibody over the IgG control treatment group in
C57BL/6 mice at 3 days after infection, but the data did not reach
significance (A). In BALB/c mice, fewer F4/80þ and MerTKþ cells were
seen after IL-17 antibody treatment compared with IgG control
treatment at 3 days after infection. (B). No difference was detected
for MerTKþ cells or macrophages (F4/80þ) between IL-10 neutralizing
antibody and IgG treatment groups in BALB/c mice at 3 days after
infection (C).
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